Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Ann Cardiothorac Surg. 2013 Jul;2(4):467-74. doi: 10.3978/j.issn.2225-319X.2013.06.02.
improved quantification of coronary artery disease by the SYNTAX score, new-generation drug-eluting stents and increased use of stents for multivessel disease, ongoing evaluation of stents for left main disease, new strategies for minimally invasive coronary artery bypass grafting (CABG) including the use of robotic-assisted CABG, hybrid procedures, and off pump CABG. In comparisons of all these strategies, the impact on survival is arguably the most important parameter. It has long been accepted that using the left internal mammary artery (LIMA) to bypass the left anterior descending coronary artery (LAD) is the gold standard and may confer the survival advantage reported for CABG compared with percutaneous coronary intervention in the literature. The survival advantage of using additional arterial conduits as compared to the conventional use of LIMA with saphenous veins only has long been debated. Our study, which involved a large cohort of 8,622 patients with multivessel disease, followed over a long period of time, has shown that in primary isolated CABG surgery performed more than 15 years ago with the use of LIMA to the LAD, bypassing the non-LAD targets with at least 1 additional arterial graft, either the right internal mammary artery and/or the radial artery, was an independent predictor of increased survival during the following 15 years. The results were confirmed with both a propensity-matched analysis that included 1,153 patients in each group and a multivariate analysis that was able to control for all differences between the groups because of the power of the large cohort in this series. The significant survival advantage of coronary artery bypass surgery with the use of multiple arterial grafting cannot be ignored in patients with multivessel coronary artery disease as various revascularization strategies are considered.
通过 SYNTAX 评分、新一代药物洗脱支架和多支血管病变中支架的使用增加,对左主干疾病的支架进行持续评估,微创冠状动脉旁路移植术(CABG)的新策略,包括使用机器人辅助 CABG、杂交手术和非体外循环 CABG,对冠状动脉疾病的量化得到了改善。在所有这些策略的比较中,对生存的影响可以说是最重要的参数。长期以来,人们一直认为使用左内乳动脉(LIMA)绕过左前降支(LAD)是金标准,并且与文献中经皮冠状动脉介入治疗相比,可能带来 CABG 的生存优势。与仅使用 LIMA 和大隐静脉的传统方法相比,使用额外动脉移植物的生存优势长期以来一直存在争议。我们的研究涉及了 8622 名多支血管病变患者的大队列,随访时间较长,结果表明,在 15 年前进行的原发性孤立性 CABG 手术中,如果使用 LIMA 到 LAD,并且旁路非 LAD 靶血管至少使用 1 个额外的动脉移植物,无论是右内乳动脉还是桡动脉,都是接下来 15 年内生存率增加的独立预测因素。这些结果通过倾向匹配分析得到了证实,该分析纳入了每组 1153 名患者,以及多元分析,由于该系列中患者数量庞大,能够控制两组之间的所有差异。在考虑各种血管重建策略时,对于多支血管病变的患者来说,使用多支动脉移植的冠状动脉旁路手术的显著生存优势不容忽视。